Keagan G Lipak1, Joseph R Rausch1,2, Rachel S Fisher1, Kemar V Prussien3, Olivia E Clark1, Ansley E Kenney1, Alexandra C Himelhoch1, Randal S Olshefski2,4, Leena Nahata1,2,5, Kathryn Vannatta1,2,6, Bruce E Compas3, Cynthia A Gerhardt7,8,9. 1. Center for Biobehavioral Health, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. 2. Department of Pediatrics, The Ohio State University, Columbus, OH, USA. 3. Department of Psychology and Human Development, Vanderbilt University, Nashville, TN, USA. 4. Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH, USA. 5. Division of Endocrinology, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, 43205, USA. 6. Department of Psychology, The Ohio State University, Columbus, OH, USA. 7. Center for Biobehavioral Health, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. cynthia.gerhardt@nationwidechildrens.org. 8. Department of Pediatrics, The Ohio State University, Columbus, OH, USA. cynthia.gerhardt@nationwidechildrens.org. 9. Department of Psychology, The Ohio State University, Columbus, OH, USA. cynthia.gerhardt@nationwidechildrens.org.
Abstract
PURPOSE: Pediatric cancer survivors may have lower quality of life (QoL), but most research has assessed outcomes either in treatment or long-term survivorship. We focused on early survivorship (i.e., 3 and 5 years post-diagnosis), examining the impact of CNS-directed treatment on child QoL, as well as sex and age at diagnosis as potential moderators. METHODS: Families of children with cancer (ages 5-17) were recruited at diagnosis or relapse (N = 336). Survivors completed the PedsQL at 3 (n = 96) and 5 years (n = 108), along with mothers (101 and 105, respectively) and fathers (45 and 53, respectively). The impact of CNS treatment, sex, and age at diagnosis on child QoL was examined over both time since diagnosis and time since last treatment using mixed model analyses. RESULTS: Parent-report of the child's total QoL was in the normative range and stable between 3 and 5 years when examining time since diagnosis, while child reported QoL improved over time (p = 0.04). In terms of time since last treatment, mother and child both reported the child's QoL improved over time (p = 0.0002 and p = 0.0006, respectively). Based on parent-report, males with CNS-directed treatment had lower total QoL than females and males who did not receive CNS-directed treatment. Age at diagnosis did not moderate the impact of treatment type on total QoL. CONCLUSIONS: Quality of life (QoL) in early survivorship may be low among males who received CNS-directed treatment. However, this was only evident on parent-report. Interventions to improve child QoL should focus on male survivors who received CNS-directed treatment, as well as females regardless of treatment type.
PURPOSE: Pediatric cancer survivors may have lower quality of life (QoL), but most research has assessed outcomes either in treatment or long-term survivorship. We focused on early survivorship (i.e., 3 and 5 years post-diagnosis), examining the impact of CNS-directed treatment on child QoL, as well as sex and age at diagnosis as potential moderators. METHODS: Families of children with cancer (ages 5-17) were recruited at diagnosis or relapse (N = 336). Survivors completed the PedsQL at 3 (n = 96) and 5 years (n = 108), along with mothers (101 and 105, respectively) and fathers (45 and 53, respectively). The impact of CNS treatment, sex, and age at diagnosis on child QoL was examined over both time since diagnosis and time since last treatment using mixed model analyses. RESULTS: Parent-report of the child's total QoL was in the normative range and stable between 3 and 5 years when examining time since diagnosis, while child reported QoL improved over time (p = 0.04). In terms of time since last treatment, mother and child both reported the child's QoL improved over time (p = 0.0002 and p = 0.0006, respectively). Based on parent-report, males with CNS-directed treatment had lower total QoL than females and males who did not receive CNS-directed treatment. Age at diagnosis did not moderate the impact of treatment type on total QoL. CONCLUSIONS: Quality of life (QoL) in early survivorship may be low among males who received CNS-directed treatment. However, this was only evident on parent-report. Interventions to improve child QoL should focus on male survivors who received CNS-directed treatment, as well as females regardless of treatment type.
Authors: Pinki K Prasad; Kristina K Hardy; Nan Zhang; Kim Edelstein; Deokumar Srivastava; Lonnie Zeltzer; Marilyn Stovall; Nita L Seibel; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin Krull Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544
Authors: Vicky Lehmann; Marrit A Tuinman; Madelaine C Keim; Adrien M Winning; Randal S Olshefski; Rajinder P S Bajwa; Mariët Hagedoorn; Cynthia A Gerhardt Journal: Cancer Date: 2017-02-06 Impact factor: 6.860
Authors: Femke K Aarsen; Philippe F Paquier; Roel E Reddingius; Isabelle C Streng; Willem-Frans M Arts; Marjon Evera-Preesman; Coriene E Catsman-Berrevoets Journal: Cancer Date: 2006-01-15 Impact factor: 6.860
Authors: Pamela S Hinds; Catherine A Billups; Xueyuan Cao; Jami S Gattuso; Elizabeth Burghen; Nancy West; Jeffrey E Rubnitz; Najat C Daw Journal: Eur J Oncol Nurs Date: 2008-10-15 Impact factor: 2.398
Authors: Brad J Zebrack; Lonnie K Zeltzer; John Whitton; Ann C Mertens; Lorrie Odom; Roger Berkow; Leslie L Robison Journal: Pediatrics Date: 2002-07 Impact factor: 9.703